Structure-guided design of D-galactal derivatives with high affinity and selectivity for the galectin-8 n-terminal domain

Hassan, Mujtaba (avtor), Baussière, Floriane (avtor), Guzelj, Samo (avtor), Sundin, Anders (avtor), Håkansson, Maria (avtor), Kovačič, Rebeka (avtor), Leffler, Hakon (avtor), Tomašič, Tihomir (avtor), Anderluh, Marko (avtor), Jakopin, Žiga (avtor)

Galectin-8 is a carbohydrate-binding protein that plays a crucial role in tumor progression and metastasis, antibacterial autophagy, modulation of the immune system, and bone remodeling. The design, synthesis, and protein affinity evaluation of a set of C-3 substituted benzimidazole and quinoline d-galactal derivatives identified a d-galactal-benzimidazole hybrid as a selective ligand for the galectin-8 N-terminal domain (galectin-8N), with a Kd of 48 μM and 15-fold selectivity over galectin-3 and even better selectivity over the other mammalian galectins. X-ray structural analysis of galectin-8N in complex with one benzimidazole- and one quinoline-galactal derivative at 1.52 and 2.1 Å together with molecular dynamics simulations and quantum mechanical calculations of galectin-8N in complex with the benzimidazole derivative revealed orbital overlap between a NH LUMO of Arg45 with electron rich HOMOs of the olefin and O4 of the d-galactal. Such overlap is hypothesized to contribute to the high affinity of the d-galactal-derived ligands for galectin-8N. A (3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay evaluation of the d-galactal-benzimidazole hybrid and an analogous galactoside derivative on a panel of cell lines with MTS assay showed no effect on cell viability up to 100 μM concentration. A subsequent functional assay using the MDA-MB-231 cell line demonstrated that the d-galactal-benzimidazole hybrid and the analogous galactoside derivative reduced the secretion of the proinflammatory cytokines interleukin-6 (IL-6) and IL-8 in a dose-dependent manner. Therefore, these compounds represent potential probes for galectin-8N pharmacology investigations and possibly promising leads for the design and synthesis of potent and selective galectin-8 inhibitors as potential antitumor and anti-inflammatory agents.

• Jezik: Angleški jezik
• Ključne besede: Galectin-8N, d-galactal, benzimidazole, selectivity, X-ray crystallography, cytokine secretion
• Vrsta gradiva: Članek v reviji
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: FFA - Fakulteta za farmacijo
• Status publikacije: Objavljeno
• Različica publikacije: Objavljena publikacija
• Leto izida: 2021
• Št. strani: Str. 1745-1752
• Številčenje: Vol. 12, iss. 11
• PID: 20.500.12556/RUL-141454
• UDK: 615.4:54:616-006
• ISSN pri članku: 1948-5875
• DOI: 10.1021/acsmedchemlett.1c00371
• COBISS.SI-ID: 83202819
• Datum objave v RUL: 29.09.2022

HASSAN, Mujtaba, BAUSSIÈRE, Floriane, GUZELJ, Samo, SUNDIN, Anders, HÅKANSSON, Maria, KOVAČIČ, Rebeka, LEFFLER, Hakon, TOMAŠIČ, Tihomir, ANDERLUH, Marko in JAKOPIN, Žiga, 2021, Structure-guided design of D-galactal derivatives with high affinity and selectivity for the galectin-8 n-terminal domain. ACS Medicinal Chemistry Letters [na spletu]. 2021. Vol. 12, no. 11, p. 1745–1752. [Dostopano 5 julij 2025]. DOI 10.1021/acsmedchemlett.1c00371. Pridobljeno s: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=141454

Gradivo je del revije

• Naslov: ACS Medicinal Chemistry Letters
• Založnik: American Chemical Society
• ISSN: 1948-5875
• COBISS.SI-ID: 2959217

Licence

• Licenca: CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by/4.0/deed.sl
• Opis: To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Projekti

• Financer: Drugi - Drug financer ali več financerjev
• Program financ.: Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie Grant Agreement
• Številka projekta: 765581